Back to research feed

Journal of surgical oncology

October 18, 2026 · via Europe PMC

Hepatic Adenomas in Men: Diagnostic Considerations and Management in the Modern Era.

Belledent T, Nwosu J, Brevik K, +6 more, Aziz H

ReviewAbstract only — full text under license

AI summary — for doctors, generated from the abstract only

Not all hepatic adenomas in men need resection; selected small tumors without high-risk molecular features may be managed with biopsy-guided surveillance.

What was studied

Narrative review of diagnosis and management of hepatic adenomas in men, covering subtypes, imaging, biopsy and guideline recommendations.

Key findings

  • Beta-catenin-activated and inflammatory subtypes account for most cases in men, and CTNNB1 exon 3 mutations carry the strongest malignant potential.
  • MRI with hepatobiliary contrast can suggest subtype but is imperfect, and biopsy improves precision.
  • Guidelines still recommend resection for all adenomas in men, but limited retrospective data suggest low malignant risk in small tumors without exon 3 mutations.
  • Resection remains standard for large or beta-catenin-mutated tumors.

Clinical relevance

Management of men with adenomas can be individualized rather than defaulting to surgery in every case.

Who should care

Radiation OncologyGynaecological Oncology

Limitations

The surveillance suggestion rests on limited, mostly retrospective data and does not exclude malignant transformation in small tumors.

Consider biopsy and multidisciplinary review for small indeterminate adenomas, while keeping resection for large or mutated ones.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Hepatic adenomas (HAs) are rare benign liver tumors traditionally associated with young women, yet contemporary epidemiologic trends reveal increasing recognition among men. Historically, universal resection in males has been recommended because of a nearly tenfold increased risk of malignant transformation as reported by Farges et al. in a single-institution surgical series; however, advances in molecular profiling and imaging have challenged this paradigm. β-catenin-activated and inflammatory subtypes account for most cases in men, often associated with anabolic steroid exposure, obesity, or metabolic syndrome. β-catenin-activated adenomas-particularly those harboring CTNNB1 exon 3 mutations-demonstrate the strongest correlation with malignant potential. Magnetic resonance imaging with hepatobiliary contrast agents can suggest subtype but lacks perfect accuracy; biopsy offers improved diagnostic precision and enables molecular confirmation. Current ACG and EASL guidelines still endorse routine resection for all hepatic adenomas in males; however, available retrospective data suggest that malignant transformation appears to be uncommon in small (5 cm) lesions lacking exon 3 CTNNB1 mutations; however, this observation is derived from limited, predominantly retrospective data and does not exclude the possibility of malignant transformation in this subgroup. These data support selective, biopsy-guided surveillance for small, indeterminate tumors within experienced multidisciplinary centers where longitudinal follow-up is reliable. Resection remains the standard recommendation for large or β-catenin-mutated adenomas, with minimally invasive surgery demonstrating excellent outcomes. Modern management of hepatic adenomas in men should be individualized, integrating molecular subtype, size, risk factors, and patient context. A multidisciplinary and molecularly informed strategy is essential to optimize outcomes while avoiding unnecessary intervention.

DOI

10.1002/jso.70415

PMID

42894444

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in